International Stem Cell (ISCO) Non-Current Debt (2019 - 2020)
International Stem Cell (ISCO) posted quarterly Non-Current Debt of $2.5 million for Q4 2020, up 4.43% year-over-year from $2.4 million in Q1 2020, and up 4.43% quarter-over-quarter from $2.4 million in Q4 2019.
International Stem Cell (ISCO) Non-Current Debt (2019 - 2020) Analysis & Trends
International Stem Cell (ISCO) has reported Non-Current Debt for 2 consecutive years, with $2.5 million the latest figure, recorded in Q4 2020.
- In Q4 2020, Non-Current Debt rose 4.43% year-over-year to $2.5 million; the TTM figure through Dec 2020 stood at $2.5 million (up 4.43% YoY), while the FY2020 annual figure was $2.5 million, up 4.43% from the prior year.
- Non-Current Debt rose to $2.5 million in Q4 2020 per ISCO's latest filing, from $2.4 million in the prior quarter.
- Across five years, Non-Current Debt topped out at $2.5 million in Q4 2020 and bottomed at $2.4 million in Q4 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 591.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 882.16 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | - |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 546.77 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 8.96 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 360.97 Mn |
| 10 | International Stem Cell | 4.32 Mn | 3.23 Mn | 1.46 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2020 | 2.48 Mn |
| Dec 31, 2019 | 2.37 Mn |